Predictors for the Clinical Efficacy of Tramadol for Cancer Pain.
Am J Hosp Palliat Care
; 40(12): 1303-1309, 2023 Dec.
Article
em En
| MEDLINE
| ID: mdl-36647180
ABSTRACT
CONTEXT Tramadol is conditionally recommended for cancer pain and is a less expensive drug compared to strong opioids. Thus, tramadol may help reduce health care costs. OBJECTIVES:
To investigate factors that predict the clinical efficacy of tramadol for cancer pain.METHODS:
A retrospective study using electronic medical records was conducted on patients who received tramadol for cancer pain from January 2016 to December 2020. Patients who continued tramadol for >28 days or discontinued tramadol before 28 days owing to pain improvement were considered as clinical efficacy cases.RESULTS:
We identified 183 eligible patients; 104 cases had clinical efficacy. The median starting tramadol daily dose was 100 mg, and the median administration duration was 22 days. Overall, 169 patients (92.3%) discontinued tramadol; pain improvement was the most common reason (34.9%). Age (>70 years), a performance status of 0-1, and an albumin-bilirubin grade of 1 were independent predictors for the clinical efficacy of tramadol. Patients with multiple predictors had significantly higher achievement rates than those without.CONCLUSION:
Tramadol could have greater clinical efficacy for cancer pain in patients who are elderly, have good performance status, and have good liver function.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Tramadol
/
Dor do Câncer
/
Neoplasias
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Aged
/
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article